Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Balcinrenone and Spironolactone on Serum Potassium in Heart Failure
NCT03682497Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of balcinrenone in heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by AstraZeneca. Primary endpoint: Relative change (%) from baseline in serum potassium at 28 days. Started Nov 2018; status: terminated.
02
Drugs
balcinrenone
03
Conditions
heart failure with mildly reduced ejection fraction (HFmrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03682497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682497.